Why Medical Affairs must be integrated into field strategy

Organisations are beginning to rethink field integration more holistically out of a realisation that consistency in scientific communication matters more than ever.

For many organisations, Medical Affairs (MA) is still viewed primarily as a support or review function, essential for scientific accuracy and compliance, but often operating adjacent to broader commercialisation strategy. Yet, as therapies become more complex, stakeholder expectations rise, and engagement models evolve, that view no longer reflects the role Medical Affairs actually plays across the product lifecycle.

MA teams are frequently among the first to establish meaningful scientific dialogue with healthcare professionals (HCPs), investigators, and key opinion leaders. They help organisations understand emerging evidence gaps, interpret scientific data in real-world settings, and identify the questions that matter most to physicians and patients.

In many cases, they also shape how scientific information is translated into educational content, evidence generation strategies, publications, and field engagement plans.

As such, the challenge is not whether Medical Affairs provides strategic value. The challenge is that many organisations still operationalise MA as a downstream contributor, rather than an integrated strategic partner.

The case for integration

This disconnect isn’t merely academic. Treating Medical Affairs as a later-stage input has consequences as pharmaceutical companies work to create more coordinated engagement across medical, commercial, and digital channels. As therapies become more specialised and stakeholder expectations continue to rise, consistency in scientific communication and education matters more than ever.

When engagement feels fragmented, repetitive, or disconnected across teams and channels, it can reduce both the effectiveness of communication and the overall stakeholder experience. Organisations that are succeeding in this environment are beginning to rethink field integration more holistically.

Rather than treating Medical and Commercial as parallel functions that occasionally intersect, organisations are building models that allow both groups to contribute earlier and more intentionally to engagement planning while still respecting the distinct responsibilities and compliance guardrails each function must maintain.

This was a recurring theme during a panel discussion at Pharma USA this year, focused on evolving field team models for measurable impact. One of the strongest points raised was that effective integration is not about blurring the lines between Medical and Commercial. It’s about creating operational models that allow scientific insights, stakeholder feedback, and engagement priorities to move more effectively across teams.

Fundamentally different

Medical Affairs contributes a perspective that is fundamentally different from most commercial functions. MA teams often have deeper visibility into scientific adoption barriers, treatment complexity, patient concerns, and evolving standards of care. In rare and ultra-rare disease especially, Medical Affairs may be one of the few functions engaging in detailed scientific conversations around highly specialised patient populations and treatment journeys.

Those insights can meaningfully shape broader organisational strategy. For example, Medical Affairs often helps identify where additional education is needed, which misconceptions are slowing adoption, what evidence gaps remain unresolved, and what types of content or data physicians find most credible. MAcan also help guide how organisations prioritise publications, congress activity, digital education, and field enablement resources across different stages of the product lifecycle.

Importantly, this does not diminish the role of commercial teams. Instead, it strengthens the organisation’s ability to deliver more coordinated and informed stakeholder engagement.

The field itself is also evolving. Traditional deployment models built around reach and frequency are giving way to more specialised and targeted engagement approaches. Organisations are increasingly leveraging digital channels, omnichannel orchestration, advanced analytics, and AI-driven prioritisation to determine where medical science liaisons (MSLs), for instance, can create the greatest value.

Of growing importance

In that environment, integration becomes even more important. Technology alone can’t solve fragmented engagement strategies. Without alignment among Medical, Commercial, analytics, and field teams, organisations risk creating disconnected experiences across channels and stakeholders. Data may identify where to engage, but scientific understanding and field insight are often critical in determining how engagement should occur and what information will be most meaningful.

This includes supporting field teams with scientifically relevant educational strategies, helping shape content based on real-world HCP feedback, identifying opportunities for evidence generation, and contributing to more informed account planning. In many organisations, Medical Affairs also serves as an important bridge between field insights and enterprise strategy by translating stakeholder feedback into actionable recommendations that influence future engagement priorities.

What many organisations are beginning to recognise is that effective field integration is not simply about improving coordination between departments. It is about creating a more connected experience for HCPs, patients, and caregivers who rely on timely, credible, and scientifically grounded information to make important treatment decisions.

Those stakeholders don’t experience organisations through departmental structures or internal functional boundaries. They experience them through conversations, educational resources, field interactions, and the continuity of engagement over time. When Medical and Commercial operate as disconnected teams, that experience can become fragmented. When they operate with shared visibility, aligned planning, and a common understanding of stakeholder needs, organisations are often better positioned to deliver more meaningful and effective engagement.

That shift also requires organisations to rethink how Medical Affairs is positioned internally. While MA must maintain its scientific independence and compliance responsibilities, its role should not be limited to review, escalation management, or late-stage support. Medical Affairs often contributes valuable perspective in areas ranging from evidence generation and educational strategy to field enablement, stakeholder insight development, and lifecycle planning.

Ultimately, the goal is not simply greater alignment between functions. It’s creating a more connected approach to scientific engagement and education across the product lifecycle.

HCPs, patients, and caregivers do not see separate departmental objectives. They seek trusted information, informed guidance, and meaningful support at critical moments in care. Organisations that integrate Medical Affairs more strategically into field engagement are often better positioned to deliver that experience consistently and effectively.

Because, in the end, successful field integration is not measured by organisational efficiency alone. It’s measured by an organisation’s ability to bring the right scientific knowledge, through the right channels, at the right moments, to improve outcomes for the patients who are still waiting.